课题基金 / 基金详情

基于炎性细胞-血管内皮crosstalk探讨绿原酸改善糖尿病视网膜病早期病变的作用机制

批准号:
82074084
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
季莉莉
依托单位:
学科分类:
中药内分泌与代谢药理
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
季莉莉

项目摘要

结项摘要

季莉莉的其他基金

相似基金

相关文献

中文摘要
糖尿病视网膜病(DR)是临床上最常见、最严重慢性发展的糖尿病微血管并发症之一。近年来中国糖尿病患者持续增多,已跃居世界首位,DR患病率也随之日益增长,成为成年人致盲的主要原因。中药金银花和菊花常被制成具有清暑热、利嗓、明目护眼功效的保健茶饮。绿原酸是金银花、菊花的主要活性成分,前期研究发现绿原酸可以缓解视网膜炎性损伤,逆转血-视网膜屏障破损,改善DR早期病变。本课题拟在此基础上,从抑制高糖状态下小胶质细胞中ERK1/2-NFkappaB介导的炎性反应、激活Nrf2缓解炎性诱导的视网膜血管内皮表型转化和氧应激损伤以及进一步反馈性抑制视网膜炎性渗出,揭示绿原酸通过调控炎性细胞-视网膜血管内皮间对话,维持炎性-视网膜血管稳态平衡,抑制血-视网膜屏障破损,改善DR早期病变的机制。通过课题实施为金银花、菊花传统明目活性和绿原酸在DR治疗中的潜在应用提供实验依据,也为DR病变机制的研究探索建立新思路。
英文摘要
Diabetic retinopathy (DR) is one of the most common and severe microvascular complications of diabetes mellitus (Diabetes, DM). In recent years, the number of diabetes in China continues to increase, and it has already leaped to the first place in the world. Meanwhile, the prevalence of DR is also increasing, and it has become the main reason for causing the blindness in adults. Lonicerae Japonicae Flos (Jin-Yin-Hua) and Chrysanthemi Flos (Ju-Hua) are traditionally used for clearing away heat and toxic materials. Lonicerae Japonicae Flos and Chrysanthemi Flos are commonly made into health-care teas with clearing summer-heat, beneficial to the throat and eyesight-improving capacity. Chlorogenic acid (CGA) is the main active compound in Lonicerae Japonicae Flos and Chrysanthemi Flos. In the previous study, we found that chlorogenic acid reduced retinal inflammation and attenuated blood-retinal barrier (BRB) breakdown, and thus alleviated the development of non-proliferative DR (NPDR), which is the early stage of DR. Based on the previous research, the present study aims to elucidate the alleviation of NPDR provided by CGA via attenuating BRB breakdown through maintaining the homeostasis of retinal inflammation-microvascular endothelium via regulating the crosstalk between immune cells and retinal microvascular endothelial cells by inhibiting ERK1/2-NFkappaB-initiated inflammation in microglia, reversing the oxidative stress injury and the endothelial to mesenchymal transition (EndoMT) induced by inflammation through activating Nrf2 in retinal microvascular endothelial cells and the subsequent feedback inhibition on retinal inflammatory cells exudation. The results will provide the experimental evidences for the traditional eyesight-improving activity of Lonicerae Japonicae Flos and Chrysanthemi Flos, and the potential application of CGA for DR treatment in clinic. This study will also provide a new strategy for studying the involved mechanism of DR development.
糖尿病视网膜病(DR)是临床上最常见、最严重的慢性发展的糖尿病微血管并发症之一,是成年人视力受损、甚至致盲的主要原因。绿原酸是具有明目功效中药金银花、菊花中的主要活性成分,前期研究提示其具有改善DR的活性,但是具体作用及其机制有待进一步阐明。本项目首先在体内动物上证实绿原酸具有优良地防治DR病变的药效,接下去在体内动物、体外细胞上通过运用抑制剂、基因过表达和敲除、靶点垂钓等技术手段,发现绿原酸可以通过抑制视网膜神经胶质和小胶质细胞内ERK1/2-NFB信号通路介导的炎性因子TNF、IL-6等表达和释放,缓解DR病变中视网膜的炎性反应;通过靶向结合Keap1激活视网膜血管内皮细胞和视网膜色素上皮细胞中Nrf2,启动Nrf2介导的抗氧化信号通路,逆转炎性因子TNF诱导的氧应激、内皮和上皮的表型转化,缓解DR病变中血-视网膜屏障(BRB)的破损渗漏;还可以通过靶向结合TNFR1,抑制TNF诱导的视网膜血管内皮细胞上黏附分子ICAM1和VCAM1的表达,减少外周血白细胞在视网膜血管内皮上的黏附,进一步减弱视网膜炎性损伤;从调控炎性细胞-视网膜血管内皮间的对话,维持BRB整体稳态平衡,发挥改善DR病变的作用机制;最后证实含绿原酸为主要成分的中药金银花及其复方四妙勇安汤都具有优异的改善DR病变的药效。通过研究从维持视网膜炎性-血管内皮稳态平衡的角度为DR的防治提供了新靶点、新思路,也为金银花、菊花等中药的传统明目功效提供了实验依据,更有助于提升金银花、菊花等中药及其复方制剂的药用价值。
绿原酸通过靶向肝窦内皮上TGFbetaR1调控下游ID1介导信号通路改善非酒精性脂肪性肝炎的机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    51万元
  • 批准年份:
    2022
  • 负责人:
    季莉莉
  • 依托单位:
基于炎性细胞-血管内皮crosstalk探讨绿原酸改善糖尿病视网膜病早期病变的作用机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    55万元
  • 批准年份:
    2020
  • 负责人:
    季莉莉
  • 依托单位:
绿原酸通过双重调控转录因子Nrf2和Egr1信号通路抑制对乙酰氨基酚肝毒性的机理研究
  • 批准号:
    81573679
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2015
  • 负责人:
    季莉莉
  • 依托单位:
补虚中药石斛明目活性的药效物质基础及其分子机理
  • 批准号:
    81173517
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    季莉莉
  • 依托单位:
国内基金
海外基金